Zhengye Biotechnology Holding Ltd
Zhengye Biotechnology Holding Ltd is a Cayman Islands holding company with operating activities centered in Jilin, China through its veterinary vaccine business. The company develops, manufactures, and sells veterinary vaccines, with a particular focus on livestock vaccines in China.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueVaccines designed to prevent disease in livestock and other farm animals.
Internal research, strain development, and vaccine formulation supporting product commercialization.
Production and packaging of veterinary biologics at the company's facilities in China.
Products
Reported · share of revenue- Distribution Network52.9 %
- Direct Sales Channel44.6 %
- Government Tender and Procurement2.5 %
Source: 20-F FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
The company sells primarily to livestock-focused animal health customers in China, where vaccine purchasing is tied to herd health management and disease prevention. Its buyers are typically organizations that need consistent supply of veterinary biologics for farm and production-animal use. Demand is driven by the need to protect animal populations, reduce mortality, and support productivity in livestock operations.
Buy veterinary vaccines for herd disease prevention and productivity protection.
Purchase products for resale into veterinary and agricultural channels.
Use vaccines in treatment and prevention protocols for farm animals.
Strategy
The company’s strategy is centered on building a veterinary vaccine platform spanning research, manufacturing, and sales. Its competitive position depends on maintaining product development capabilities and serving livestock health needs in China, where disease prevention is operationally important for producers. As a Nasdaq-listed Chinese operating company, it also depends on continued access to public capital markets and regulatory compliance.
New and improved vaccines support customer retention and product relevance.
Integrated production and sales are necessary to meet farm and distributor demand.
U.S. listing status supports access to capital and investor visibility.
Geography
The business is operationally centered in Jilin, China, where the company’s principal executive office and operating base are located. Its commercial focus is China, particularly livestock vaccine demand, while the company is incorporated in the Cayman Islands and listed on Nasdaq in the United States. Geography matters because manufacturing, regulatory oversight, and end-market demand are concentrated in China even though the capital markets presence is offshore.
Risks
The company is exposed to demand fluctuations in livestock health markets, regulatory requirements for veterinary biologics, and execution risks in manufacturing and product quality. As a China-centered operating business with a U.S. listing, it also faces cross-border compliance, disclosure, and market volatility risks that can affect investor confidence and access to capital.
- Livestock disease and demand variabilityImpact: HighLikelihood: Medium
Vaccine demand depends on animal health conditions and farm purchasing cycles.
Exposure: China livestock vaccine market
- Manufacturing quality and product complianceImpact: HighLikelihood: Medium
Veterinary vaccines require strict production standards and regulatory oversight.
Exposure: Vaccine manufacturing and sales
- China concentrationImpact: MediumLikelihood: High
Commercial activities are focused in one country, increasing policy and market dependence.
Exposure: Operations and end-market concentration
- Nasdaq listing and trading volatilityImpact: MediumLikelihood: Medium
Share-price volatility can affect compliance status and investor perception.
Exposure: Public listing in the United States
Accounting
Judgemental itemsVaccine sales are typically recognized when control transfers, which depends on delivery terms.
Impact: Affects reported revenue timing and quarterly comparability
Biological products may face expiry, slow movement, or write-down risk.
Impact: Affects cost of sales and gross margin
Production cost allocation can materially change unit costs for vaccine products.
Impact: Affects gross profit and inventory carrying values
Manufacturing assets and facilities may require impairment testing if utilization changes.
Impact: Affects operating results and asset values
Similar listed companies
Publicly listed companies with a comparable business focus.
Jyong Biotech Ltd.
MENS · Pharmaceutical Preparations
Cellyan Biotechnology Co., Ltd
HKPD · Wholesale-Drugs, Proprietaries & Druggists' Sundries
Cellyan Biotechnology Co., Ltd is a Cayman Islands holding company with operating subsidiaries in Hong Kong that serve the OTC pharmaceutical cross-border trade market.
Zhongchao Inc.
ZCMD · Services-Educational Services
Zymeworks Inc.
ZYME · Pharmaceutical Preparations
BGM Group Ltd.
BGM · Pharmaceutical Preparations
BGM Group Ltd is a Cayman Islands holding company with operating businesses primarily conducted through subsidiaries and variable interest entities in mainland China.
Sentage Holdings Inc.
SNTG · Finance Services
Last updated: 28/09/2026